The UK and US have forged a major commercial pact that will keep zero import taxes on British medicine products being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these key products will remain at zero for a timeframe of 36 months.
This deal comes after recent statements to dramatically increase duties on branded drug imports, with figures discussed up to 100%.
"This arrangement between the UK strengthens the international landscape for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Trade Importance
Medicines represent one of the the United Kingdom's largest export categories to the United States, which is by far the largest market for large UK drugmakers.
Export figures indicate that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This deal protects work, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," a government official commented.
Detailed British Pledges
The agreement involves several key changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be restricted at 15%. In the past, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a ongoing row between the pharmaceutical industry and the UK government over spending levels and regulatory access.
This friction were exacerbated by assertions that American customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the last ten years.
